HOME >> MEDICINE >> NEWS
Twice daily imatinib could improve outcome for people with specific form of gastro-intestinal cancer

This release is also available in German.

Results of a randomised trial in this week's issue of THE LANCET suggest that a single daily 400 mg dose of imatinib--known to be a first-choice treatment for gastro-intestinal stromal tumours (GIST)--is sufficient to induce a therapeutic response; a doubling of a daily dose can slightly improve progression-free survival for patients.

Imatinib is approved worldwide for use in GIST, tumours which do not respond to conventional chemotherapy, which have a prevalence of around 20 per 100,000 population. Jaap Verweij (Erasmus University Medical Center, Netherlands) and colleagues from the European Organisation for Research and Treatment of Cancer (EORTC), the Italian Sarcoma Group (IRG), and the australasian Gastrointestinal Trials Group (AGITG) studied 946 patients with metastatic GIST who were randomly allocated either imatinib 400 mg once or twice a day.

50% of patients receiving two doses of imatinib a day, compared with 56% of patients given a single dose, were alive and free of disease progression at around 2 years follow-up. There was no difference in the proportion of patients (99%) who reported treatment side-effects; the optimum time for therapeutic effect after the start of treatment did not differ between the two groups (around 4 months).

Dr Verweij comments: "If the aim of treatment is response induction, a daily dose of 400 mg given for 46 months seems to be sufficient. However, in patients with widespread metastatic disease, the prolonged progression-free survival achieved with 400 mg twice daily might lead one to favour this regimen. Whether a similar outcome could be achieved with fewer side-effects by making use of the reduction in drug clearance over time--eg, with a starting dose of 400 mg daily followed by stepwise dose escalation to 400 mg twice a day--is still a matter for further clini
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
23-Sep-2004


Page: 1 2

Related medicine news :

1. Study: Among Heart Failure Patients, Women Survive Twice As Long As Men
2. Bullying among sixth graders a daily occurrence, UCLA study finds
3. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
4. African children with HIV would benefit from daily doses of cheap antibiotic
5. Weekend use matches daily drops for lazy eye
6. New ways identified to treat lazy eye in children: Beyond eye patches and daily drops
7. Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment
8. Study finds once-daily Valcyte prevents serious viral infection after kidney transplant
9. Max daily OTC dose of acetaminophen shows efficacy comparable to Rx doses of naproxen for OA pain
10. New study finds even a small amount of psoriasis can negatively impact daily life
11. OHSU study shows four daily servings of fruits & vegetables reduce breast cancer risk by half

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology:
Cached News: